The data underlying the results presented in the study are available from the National Health Insurance Sharing Service at <https://nhiss.nhis.or.kr/bd/ab/bdabb006iv.do>. Upon an individual researcher\'s data set request, NHIS provides customized data to the researcher.

Introduction {#sec005}
============

Proton pump inhibitors (PPIs) are effective gastric-acid-suppressing medications used for the treatment of various gastrointestinal disorders, such as gastrointestinal ulcers, esophagitis, hyperacidity, *Helicobacter pylori* infection, and gastro esophageal reflux disease (GERD) \[[@pone.0235163.ref001], [@pone.0235163.ref002]\]. In Korea, the number of patients using PPIs has increased annually with the 2013 rate being 11.5 times that of the 2003 rate \[[@pone.0235163.ref003]\].

The increase in PPI usage may be associated with an increase in the number of indicated patients. According to data from the National Health Insurance of Korea, the number of patients treated for peptic ulcer or GERD, the main indications for PPIs, has increased by about 13% over the last 8 years (2017 vs. 2010) \[[@pone.0235163.ref004]\]. Whilst the incidence of peptic ulcer has decreased, GERD, which has increased 1.5-fold over the period from 2010 to 2017, appears to have contributed significantly to this trend \[[@pone.0235163.ref004]\]. GERD is a chronic disease that is prone to recurrence, and symptoms can improve or worsen; thus, some patients require long-term treatments. The increase in patients with GERD has resulted in an increase in the number of patients using PPIs, as well as the duration of their administration \[[@pone.0235163.ref003]\]. In addition, the use of PPIs is recommended to prevent gastrointestinal bleeding complications in patients who use two or more antiplatelet drugs \[[@pone.0235163.ref005]\], and this has contributed to the continuous increase in the long-term use of PPIs, particularly among elderly patients.

Bisphosphonate (BP), commonly used to prevent osteoporotic fractures, has a major adverse effect on the upper gastrointestinal tract, including esophageal inflammation, ulceration, and dyspepsia \[[@pone.0235163.ref006]--[@pone.0235163.ref010]\]. Hence, it is expected that BP is administered in combination with a PPI to prevent or treat the adverse events \[[@pone.0235163.ref011]\]. Identifying whether the association between PPI use and the risk of fractures depends on BP use may provide clinical evidence that informs drug selection and improves the anti-fracture effect of BP and the safety of PPI use.

Epidemiological studies have been reported on the association between risk of fractures and PPI use \[[@pone.0235163.ref010], [@pone.0235163.ref012]--[@pone.0235163.ref014]\]. In particular, some studies have reported higher risk of fracture in BP users due to the interaction of BP and PPIs \[[@pone.0235163.ref015], [@pone.0235163.ref016]\]. These associations differ among races, indicating a higher risk of fracture in Asians than in Europeans (pooled odds ratio (OR): 1.75 vs. 1.42) \[[@pone.0235163.ref015]\]. One study that demonstrated the interaction between BP and PPIs in Asians was a case-control study conducted by Lee et al. in Korea \[[@pone.0235163.ref016]\]. In this study, the aOR was 1.30 (95% confidence interval (CI): 1.19--1.42) in BP non-users, which was significantly different from the 1.71 (95% CI: 1.31--2.23) found in BP users, and only BP users showed a trend of increasing risk with a cumulative PPI dose \[[@pone.0235163.ref016]\]. However, a study done by Itoh et al. performed in Japan showed different results \[[@pone.0235163.ref006]\]. It showed that BP administration in combination with PPIs may be more effective not only for increasing bone mineral density (BMD) but also improving physical fitness than treatment with BP alone \[[@pone.0235163.ref006]\].

The association between PPI use and the risk of fractures (hip, wrist or spine) is known to be stronger when the PPI is used at high doses or over a long-term period \[[@pone.0235163.ref017]\]. However, studies about the interaction between BP and PPIs and the risk of fracture are based on the analysis of data over a short observation period; therefore, the studies lack information on long-term users. Therefore, we need to reconfirm the influence of the interaction between BP and PPIs on fracture risk in long-term PPI users.

The purpose of this study was to reconfirm the association between fracture risks according to the PPI usage period and to reconfirm the interaction between BP and PPIs in long-term users based on the Korean National Health Insurance database. The results of this study could be used by clinicians to prescribe safer and more effective treatments for gastrointestinal ailments in elderly patients with a history of long-term PPI usage, especially women aged 65 and older who are at high risk of fractures.

Materials and methods {#sec006}
=====================

Data source and ethical considerations {#sec007}
--------------------------------------

Data from the period January 2007 to December 2017 from the Korean National Health Insurance Sharing Service (NIHSS) database were used. The Korean NIHSS system includes the entire national population (\~50 million people), and the database was established for claim reimbursements. Data on subject characteristics, clinical information, socioeconomic level of the beneficiary, and death records were included in the database. Clinical information including disease diagnosis codes based on the International Codes of Disease 10th Edition (ICD-10) Clinical Modification, treatments based on drug prescriptions, and health care costs were recorded.

Patients were not directly involved in the research, and only the secondary electronic database was used for the analysis. Informed consent was not required as the database maintained de-identification and anonymity of sampled individuals. This study was approved by the Cha University Institutional Review Board (protocol ID: 1044308-201703-HR021-01).

Study design and selection of cases and controls {#sec008}
------------------------------------------------

A nested case-control design was applied to this study. The study population included elderly women aged ≥65 years with claims for peptic ulcer or GERD (ICD 10 code: K21, K25--28) from January 2010 to June 2017. We excluded patients who had a claim for any cancer (ICD 10 code: C) or Paget's disease (ICD 10 code: M88) during the study period (from 2007 to 2017).

The study subjects were grouped into cases and controls. Those who had sustained at least one osteoporotic fracture were classified as cases.

An osteoporotic fracture was defined as a diagnosis of osteoporosis (ICD10 code: M81, M82) before the fracture or within three months of the fracture (wrist \[ICD10 code: S422, S423, S525, S526\], spine \[ICD10 code: 10 code: M484, M485, S220, S221\], hip \[ICD10 code: S720, S721, S722\]) or osteoporosis with a current pathological fracture (ICD10 code: M80). For controls who had no history of osteoporotic fracture, each control was assigned the same event date as the fracture event date of the corresponding matched case according to the index date (date of the first diagnosis of gastrointestinal disorders) and age at the event date. The observation period was set for three years prior to the event date. Patients who sustained any fracture including an osteoporotic fracture during the observation period were excluded from participating as a case or a preliminary control subject. After excluding patients with a fracture history, the final controls were selected through 1:2 matching of cases to controls on the basis of the presence of osteoporosis (ICD10 code: M80, 81, 82) and the Charlson comorbidity index (CCI) during the period 1 year prior to the event date.

Exposure assessment {#sec009}
-------------------

A PPI user was defined as a patient who received at least one PPI prescription during the observation period. PPIs considered in this study were those containing any of the seven ingredients (omeprazole, lansoprazole, dexlansoprazole, esomeprazole, pantoprazole, rabeprazole, ilaprazole) listed in the Korean National Health Insurance Formulary.

In order to compare the fracture OR for the PPI users according to the duration of exposure to PPI, we defined the duration of exposure to PPI as the total number of PPI prescription days during the 3-year observation period and divided it into five quintiles: less than 1 month (\< 30 days), 1--3 months (30--89 days), 3--6 months (90--179 days), 6--12 months (180--364 days), and 1 year or more (≥ 365 days). Since fractures that occurred more than 1 year after the last exposure to PPI can hardly be associated with the exposure to PPI, a sub-analysis was carried out on the patients who had sustained fractures within 12 months from the last day of PPI medication use after excluding the patients who had not used PPIs for 1 year or more prior to the fracture.

Statistical analysis {#sec010}
--------------------

As for the characteristics of the cases and controls, categorical variables were presented as frequency and percentage and continuous variables (age, CCI) as mean and standard deviation (SD). In order to determine whether the characteristics of the cases and controls were significantly different, statistical analysis was performed using a student's t-test or chi-squared test, as appropriate.

For each patient, comorbidities that are known risk factors for fracture were evaluated based on the ICD-10 codes indicated in any claim made within 12 months of the event date. The evaluated diseases were: rheumatoid arthritis (M05, M06, M45), hyperthyroidism (E05), chronic kidney disease (N18), chronic obstructive pulmonary disease (J44, J45), hypopituitarism (E23.0), hyperparathyroidism (E21), Cushing's syndrome (E24), vitamin D deficiency (E55.9), idiopathic hypercalciuria (E83.5), diabetes (E11-E14), hypertension (I10-I13, I15), chronic liver disease (K72.1, K73, K74), systemic lupus erythematosus (M32), inflammatory bowel disease (K50, K51), and osteoporosis (M80, M81). Concomitant medications included in the prescriptions issued 1 year before the event date were evaluated. The evaluated medications, as the risk factors for fracture were as follows: antiplatelets, non-steroidal anti-inflammatory drugs, glucocorticoids, anticonvulsants, anticoagulants, selective serotonin reuptake inhibitors, benzodiazepines, and tricyclic antidepressants. Bisphosphonate (BP), hormone replacement therapy, and other anti-osteoporotic medications were considered preventive factors of fractures. As patient lifestyle variables, we evaluated alcohol use, smoking, physical exercise, and body mass index (BMI) using the health checkup data issued closest to the event date. The influence of the interaction between BP and PPIs on fracture risk was evaluated by analyzing the OR for fracture according to the use of BP. To this end, we defined a case with at least one prescription of BP during the observation period as a BP-user and a case with no history of prescription as a BP non-user.

Conditional logistic regression was performed to determine the association between PPI use and fracture risk. Results were presented as an aOR and 95% confidence interval (CI). The interaction between PPIs and BP was determined by calculating the aOR after dividing the dataset into BP user and non-user groups. All data were analyzed statistically using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA), and statistical significance was set at p \< 0.05 for a two-sided test.

Results {#sec011}
=======

A total of 151,155 women aged 65 years and over were diagnosed with peptic ulcer disease (PUD) or GERD between January 2010 and June 2017. Of them, 21,754 patients were selected as cases of osteoporotic fracture and 43,508 patients as controls with no history of fracture after the preliminary matching based on age and final date and the final matching based on the diagnosis of osteoporosis and CCI score ([Fig 1](#pone.0235163.g001){ref-type="fig"}).

![Flowchart of case and control selection.\
PUD: Peptic ulcer disease, GERD: gastroesophageal reflux disease, HIV: human immunodeficiency virus; CCI, Charlson comorbidity index.](pone.0235163.g001){#pone.0235163.g001}

Cases and controls were well-matched in terms of mean age (74 years), CCI score (1.83--1.85), and diagnosis of osteoporosis (32--34%). The controls showed a higher proportion in the 1st--3rd income quintiles, and the cases in the 4th and 5th income quintiles. A higher proportion of the cases lived in urban areas, and a higher proportion of the controls lived in metropolitan areas. The cases had higher comorbidity rates than the controls with regard to the diseases considered to be risk factors for fracture. The proportion of patients with concomitant medications known to increase fracture risk was also higher in the cases, as was the proportion of patients receiving anti-osteoporotic treatments other than hormone replacement therapy ([Table 1](#pone.0235163.t001){ref-type="table"}).

10.1371/journal.pone.0235163.t001

###### Demographic and clinical information for cases and controls.

![](pone.0235163.t001){#pone.0235163.t001g}

                                                                                     Cases          Controls       p-value           
  ----------------------------------------------------- ---------------------------- -------------- -------------- --------- ------- ---------
  Age, years                                            Mean (SD)                    74.21 (6.23)   73.93 (6.88)   Matched           
                                                        Median                       73             73                               
  Income level                                          1st quintile                 2,883          13.25          6,753     15.52   \<0.001
                                                        2nd quintile                 1,900          8.73           4,249     9.77    
                                                        3rd quintile                 2,504          11.51          5,323     12.23   
                                                        4th quintile                 3,835          17.63          7,230     16.62   
                                                        5th quintile                 7,744          35.60          12,103    27.82   
                                                        unknown                      2,888          13.28          7,854     18.05   
  Residence[\*](#t001fn002){ref-type="table-fn"} area   Metropolitan                 3,455          15.88          8,030     18.46   \<0.001
  Cities                                                4,707                        21.64          9,213          21.18             
  Rural areas                                           13,592                       62.48          26,269         60.38             
  CCI[\*\*](#t001fn003){ref-type="table-fn"}            Mean (SD)                    1.85 (1.94)    1.83 (1.83)    Matched           
                                                        0--2                         14,917         68.57          30,639    70.42   
                                                        ≥3                           6,837          31.43          12,873    29.59   
  Comorbidity[\*\*](#t001fn003){ref-type="table-fn"}    Rheumatism                   2,135          9.81           2,232     5.13    \<0.001
                                                        Hyperthyroidism              506            2.33           822       1.89    0.0002
                                                        Chronic kidney disease       401            1.84           632       1.45    0.0002
                                                        COPD                         5,212          23.96          7,958     18.29   \<0.001
                                                        Hypopituitarism              23             0.11           28        0.06    0.0745
                                                        Hyperparathyroidism          68             0.31           85        0.20    0.0035
                                                        Cushing's syndrome           74             0.34           42        0.10    \<0.001
                                                        Vitamin D deficiency         488            2.24           536       1.23    \<0.001
                                                        Idiopathic hypercalciuria    624            2.87           655       1.51    \<0.001
                                                        Diabetes                     7,659          35.21          13,182    30.30   \<0.001
                                                        Hypertension                 14,795         68.01          26,500    60.91   \<0.001
                                                        Chronic hepatic disease      729            3.35           1,240     2.85    0.0004
                                                        SLE                          26             0.12           37        0.09    0.1811
                                                        IBD                          59             0.27           73        0.17    0.0056
                                                        Osteoporosis                 14,381         33.89          13,772    31.65   Matched
  Medication[\*\*](#t001fn003){ref-type="table-fn"}     Antiplatelet                 8,148          37.46          14,139    32.50   \<0.001
                                                        NSAID                        20,164         92.69          32,571    74.86   \<0.001
                                                        Glucocorticoid               10,593         48.69          16,362    37.61   \<0.001
                                                        Anticonvulsant               3,271          15.04          3,998     9.19    \<0.001
                                                        Anticoagulant                1,681          7.73           1,999     4.59    \<0.001
                                                        SSRI                         1,562          7.18           1,832     4.21    \<0.001
                                                        Benzodiazepine               13,590         62.47          20,371    46.82   \<0.001
                                                        Tricyclic antidepressant     2,404          11.05          2,970     6.83    \<0.001
                                                        Bisphosphonate               10,493         48.23          7,008     16.11   \<0.001
                                                        HRT                          239            1.10           673       1.55    \<0.001
                                                        Other osteoporosis therapy   1,524          7.01           956       2.20    \<0.001
  Smoking[\*\*\*](#t001fn004){ref-type="table-fn"}      Yes                          355            1.63           830       1.91    \<0.001
                                                        No                           15,704         72.19          29,721    68.31   
                                                        Unknown                      5,695          26.18          12,961    29.79   
  Alcohol[\*\*\*](#t001fn004){ref-type="table-fn"}      Over allowance               62             0.29           125       0.29    0.8445
                                                        Under allowance              5,357          24.63          10,805    24.83   
                                                        Unknown                      16,335         75.09          32,582    74.89   
  Exercise[\*\*\*](#t001fn004){ref-type="table-fn"}     Yes                          2,942          13.52          6,137     14.11   \<0.001
                                                        No                           5,906          27.15          9,806     22.54   
                                                        Unknown                      12,904         59.32          27,569    63.37   
  BMI%[\*\*\*](#t001fn004){ref-type="table-fn"}         Mean (SD)                    23.86 (3.38)   24.29 (3.41)   \<0.001           

SD: standard deviation, BMI: body mass index, CCI: Charlson's Comorbidity Index, COPD: chronic obstructive pulmonary disease, SLE: systemic lupus erythematosus, IBD: inflammatory bowel disease, SSRI: selective serotonin reuptake inhibitors, NSAID: nonsteroidal anti-inflammatory drug: HRT, hormone replacement therapy.

\* Definitions of residential areas: Metropolitan: A local government with boroughs; Cities: A local government with a population of 50,000 or more without a borough; Rural area: A local government with a population less than 50,000

\*\*During 1-year before event date

\*\*\*Date closest to event date.

The overall crude OR for fractures according to PPI use was 1.39 (95% CI: 1.35--1.44), which indicated a statistically significant association between PPI use and fracture risk. Even after adjusting for comorbidities and concomitant medications, and the aOR stood at 1.15 (95% CI: 1.11--1.20), demonstrating that the association remained statistically significant ([Table 2](#pone.0235163.t002){ref-type="table"}).

10.1371/journal.pone.0235163.t002

###### Osteoporotic fracture risk related to proton pump inhibitor use according to the duration of exposure stratified by the use of bisphosphonate.

![](pone.0235163.t002){#pone.0235163.t002g}

                 Proton pump inhibitor use   Cases (n = 21,754)   Control (n = 43,508)   Crude[\*](#t002fn002){ref-type="table-fn"} odds ratio   Adjusted[\*\*](#t002fn003){ref-type="table-fn"} odds ratio                       
  -------------- --------------------------- -------------------- ---------------------- ------------------------------------------------------- ------------------------------------------------------------ ------------------- -------------------
  All            Unexposed                   9,201                42.3                   21,858                                                  50.2                                                         Reference           
                 Exposed                     12,553               57.7                   21,650                                                  49.8                                                         1.39 (1.35, 1.44)   1.15 (1.11, 1.20)
                 \<30 days                   5,012                23.0                   10,196                                                  23.4                                                         1.18 (1.13, 1.23)   1.03 (0.98, 1.08)
                 ≤30 days, \<90 days         3,282                15.1                   5,712                                                   13.1                                                         1.39 (1.32, 1.46)   1.12 (1.06, 1.19)
                 ≤90 days, \<180 days        1,554                7.1                    2,417                                                   5.6                                                          1.57 (1.46, 1.68)   1.23 (1.14, 1.34)
                 ≤180 days, \<365 days       1,237                5.7                    1,717                                                   3.9                                                          1.76 (1.63, 1.90)   1.35 (1.23, 1.49)
                 ≤365 days                   1,468                6.7                    1,608                                                   3.7                                                          2.24 (2.08, 2.42)   1.72 (1.57, 1.89)
  BP non-users   Unexposed                   5,075                40.0                   5,515                                                   43.7                                                         Reference           
  Exposed        7,597                       60.0                 7,093                  56.3                                                    1.22 (1.14, 1.30)                                            1.11 (1.03, 1.20)   
  \<30 days      2,916                       23.0                 3,008                  23.9                                                    1.07 (0.98, 1.16)                                            1.01 (0.92, 1.11)   
                 ≤30 days, \<90 days         1,976                15.6                   1,955                                                   15\.                                                         1.18 (1.07, 1.30)   1.06 (0.95, 1.18)
                 ≤90 days, \<180 days        973                  7.7                    904                                                     7.2                                                          1.19 (1.05, 1.36)   1.05 (0.91, 1.21)
                 ≤180 days, \<365 days       799                  6.3                    623                                                     4.9                                                          1.54 (1.34, 1.78)   1.36 (1.16, 1.60)
                 ≤365 days                   933                  7.4                    603                                                     4.8                                                          1.86 (1.61, 2.14)   1.64 (1.40, 1.92)
  BP Users       Unexposed                   4,126                45.4                   16,343                                                  52.9                                                         Reference           
  Exposed        4,956                       54.6                 14,557                 47.1                                                    1.36 (1.29, 1.44)                                            1.15 (1.08, 1.22)   
                 \<30 days                   2,096                23.1                   7,188                                                   23.3                                                         1.14 (1.06, 1.22)   0.99 (0.92, 1.07)
                 ≤30 days, \<90 days         1,306                14.4                   3,757                                                   12.2                                                         1.49 (1.36, 1.62)   1.22 (1.10, 1.34)
                 ≤90 days, \<180 days        581                  6.4                    1,513                                                   4.9                                                          1.52 (1.35, 1.72)   1.27 (1.11, 1.46)
                 ≤180 days, \<365 days       438                  4.8                    1,094                                                   3.5                                                          1.68 (1.46, 1.93)   1.33 (1.13, 1.55)
                 ≤365 days                   535                  5.9                    1,005                                                   3.3                                                          2.12 (1.85, 2.43)   1.79 (1.53, 2.09)

BP: bisphosphonate.

\* Calculated by conditional logistic regression.

\*\* Calculated by conditional regression adjusted for Charlson's comorbidity index, comorbidity, and medication.

Analysis performed separately on the BP user and non-user groups revealed the OR for fracture among BP users to be higher than that among non-users \[aOR: 1.15 (95% CI: 1.08--1.92), vs. 1.11, (1.03--1.20)\], demonstrating a statistically significant interaction between PPIs and BP (p\<0.01). In both BP user and non-user groups, the OR for fracture increased as the duration of PPI use increased, showing that there is a positive dose-response relationship between PPI use and risk of osteoporotic fracture.

The sub-group analysis performed on the patients exposed to PPI within 12 months prior to fracture showed a higher OR compared with the base analysis (aOR 1.19 vs. 1.15), whereby all ORs increased regardless of the duration of exposure or BP use ([Table 3](#pone.0235163.t003){ref-type="table"}).

10.1371/journal.pone.0235163.t003

###### Osteoporotic fracture risk among patients exposed to proton pump inhibitor within 1 year prior to fracture date.

![](pone.0235163.t003){#pone.0235163.t003g}

                 Proton pump inhibitor use   Cases (n = 17,902)   Control (n = 35,665)   Crude[\*](#t003fn002){ref-type="table-fn"} odds ratio   Adjusted[\*\*](#t003fn003){ref-type="table-fn"} odds ratio                       
  -------------- --------------------------- -------------------- ---------------------- ------------------------------------------------------- ------------------------------------------------------------ ------------------- -------------------
  All            Unexposed                   9,201                51.4                   21,858                                                  61.3                                                         Reference           
                 Exposed                     8,701                48.6                   13,807                                                  38.7                                                         1.54 (1.48, 1.60)   1.19 (1.13, 1.24)
                 \<30 days                   2,840                15.9                   5,486                                                   15.4                                                         1.26 (1.19, 1.33)   1.02 (0.96, 1.09)
                 ≤30 days, \<90 days         2,187                12.2                   3,622                                                   10.2                                                         1.49 (1.40, 1.59)   1.11 (1.03, 1.20)
                 ≤90 days, \<180 days        1,212                6.8                    1,768                                                   5.0                                                          1.73 (1.59, 1.88)   1.30 (1.17, 1.44)
                 ≤180 days, \<365 days       1,067                6.0                    1,416                                                   4.0                                                          1.84 (1.68, 2.01)   1.36 (1.22, 1.52)
                 ≤365 days                   1,395                7.8                    1,515                                                   4.2                                                          2.24 (2.06, 2.44)   1.71 (1.55, 1.89)
  BP non-users   Unexposed                   5,075                48.8                   5,515                                                   53.9                                                         Reference           
  Exposed        5,319                       51.2                 4,710                  46.1                                                    1.31 (1.21, 1.42)                                            1.13 (1.03, 1.23)   
  \<30 days      1,649                       15.9                 1,651                  16.1                                                    1.11 (0.99, 1.24)                                            0.99 (0.87, 1.12)   
                 ≤30 days, \<90 days         1,333                12.8                   1,273                                                   12.4                                                         1.19 (1.05, 1.35)   1.00 (0.87, 1.15)
                 ≤90 days, \<180 days        766                  7.4                    702                                                     6.9                                                          1.35 (1.15, 1.57)   1.15 (0.96, 1.37)
                 ≤180 days, \<365 days       682                  6.6                    514                                                     5.0                                                          1.65 (1.39, 1.95)   1.39 (1.15, 1.68)
                 ≤365 days                   889                  8.6                    570                                                     5.6                                                          1.84 (1.57, 2.15)   1.60 (1.34, 1.92)
  BP users       Unexposed                   4,126                55.0                   16,343                                                  64.2                                                         Reference           
  Exposed        3,382                       45.0                 9,097                  35.8                                                    1.50 (1.40, 1.60)                                            1.21 (1.12, 1.30)   
                 \<30 days                   1,191                15.9                   3,835                                                   15.1                                                         1.21 (1.11, 1.33)   1.03 (0.93, 1.14)
                 ≤30 days, \<90 days         854                  11.4                   2,349                                                   9.2                                                          1.64 (1.47, 1.83)   1.27 (1.12, 1.44)
                 ≤90 days, \<180 days        446                  5.9                    1,044                                                   4.1                                                          1.67 (1.43, 1.95)   1.31 (1.10, 1.56)
                 ≤180 days, \<365 days       385                  5.1                    902                                                     3.5                                                          1.67 (1.42, 1.97)   1.25 (1.04, 1.50)
                 ≤365 days                   506                  6.7                    945                                                     3.7                                                          2.14 (1.84, 2.49)   1.73 (1.46, 2.06)

BP: bisphosphonate.

\* Calculated by conditional logistic regression.

\*\* Calculated by conditional regression adjusted for Charlson's comorbidity index, comorbidity, and medication.

Discussion {#sec012}
==========

In this nested case-control study, we investigated the association between the use of PPIs and the risk of osteoporotic fracture in elderly women (≥65 years) at high risk of osteoporotic fracture. While 57.7% of cases used PPIs, 49.8% in the control group used PPIs, showing a statistically significant association between PPI use and fracture risk (aOR: 1.15, 95% CI: 1.11--1.20). The correlation analysis between fracture risk and the duration of PPI exposure showed that the risk of osteoporotic fracture increased with an increase in the duration of PPI exposure. This tendency was pronounced in the BP user group (aOR: 1.15, 95% CI: 1.08--1.22), which had a higher OR than the BP non-user group (aOR: 1.11, 95% CI: 1.03--.20); thus, verifying the interaction between PPIs and BP and the influence on fracture risk.

The finding of this study that PPI use increases the risk of fracture is consistent with that of recent meta-analyses performed by Eom et al. based on the papers published up to 2010. They reported the OR for fracture associated with PPI use to be 1.29 (95% CI: 1.18--1.41) \[[@pone.0235163.ref017]\]. Another meta-analysis performed on observational studies published up until February 2015 reported a moderate association between femoral and vertebral fractures and PPI use (relative risk of femoral fracture: 1.26; 95% CI: 1.16--1.36, relative risk of vertebral fracture: 1.58; 95% CI: 1.3--1.82) \[[@pone.0235163.ref018]\]. The most recent systematic review and meta-analysis of the studies published up until February 2018 also reported an increased risk of fracture associated with PPI use (effect size: 1.28; 95% CI: 1.22--1.35). However, with regard to the association between the duration of PPI use and increased fracture risk, researchers have reported differing results. Whilst the meta-analysis conducted by Eom and Zhou reported that PPI use for more than 1 year and less than 1 year showed similar risk levels, Nassar and Richter \[[@pone.0235163.ref019]\] noted that fracture risk did increase with an increase in the duration of PPI use. Such discrepancies may be ascribable to the limitation associated with calculating the accurate number of days of drug exposure due to different calculation methods inherent in observational studies. We must also consider that PPIs are not taken continuously or taken for a long time, but are administered when needed to patients with PUD or GERD, which are major indications for PPIs, for a finite period of time and then discontinued. If only the first exposed event from the index date is considered, or if the length of the observation period varies for each subject, the cumulative impact of PPI may be underestimated. In this study, the number of days of drug exposure was calculated by summing the PPI prescription days during the observation period (3 years prior to the fracture event date), regardless of whether PPI use was continuous. Assuming that increase in the risk of fractures with PPI is related to bone metabolism \[[@pone.0235163.ref020]--[@pone.0235163.ref022]\], recovery of the weakened bones is difficult; further, discontinuation of PPI does not immediately increase bone strength. Thus, it is reasonable to evaluate the fracture risk by calculating the cumulative exposure period of PPI by summing the cumulative PPI prescription days during the constant pre-defined observation period, and the positive dose response relationship shown in this study supports the causality between PPI use and fracture risk.

When comparing the results of this study with those of the study conducted by Lee et al. using the Korean National Health Insurance claim database, both showed that the use of PPIs increased the risk of fracture, but the aOR of this study was much lower (1.34 vs. 1.15) \[[@pone.0235163.ref016]\]. This may be explained by the fact that the mean age of the subjects in the study conducted by Lee et al. was higher than that in this study (77 vs. 74 years) and the overall study period was shorter (1.5 vs. 3 years). In other words, the association between PPI use and fracture incidence may have been overestimated because the period between the exposure and the incidence of fracture was relatively short and the corresponding patients were elderly. The analysis data used in Lee et al.'s study covers the years 2005 and 2006. It should be kept in mind that PPI use increased rapidly with the expansion of its coverage by insurance in 2008 \[[@pone.0235163.ref003]\], and therefore, the pattern of PPI use might have been different compared to PPI use patterns after 2010, which was the study period of our study. Furthermore, unlike this study, which only included PUD and GERD patients in its analysis, Lee et al.'s study did not set such inclusion criteria, and the clinical characteristics of the PPI user and non-user groups may have influenced the fracture incidence. Considering that PPI mediates risk factors, thus increasing fracture risk, the PPI prescription practice and the characteristics of PPI users can influence the study outcome. For instance, when rigorous insurance coverage criteria were applied to PPIs, PPIs were most likely administered to patients with severe gastrointestinal disorders who might have ingested a different quality of meals compared to patients without gastrointestinal disorders, and factors such as gastrointestinal malabsorption might have influenced their fracture risk. Therefore, this study was designed as a cohort study composed of gastrointestinal patients in order to minimize the effects of fracture on the patients' gastrointestinal disorders.

Although the mechanism by which PPIs increase fracture risk is yet to be determined, researchers have suggested that the increase in gastric acidity caused by PPI intake may adversely affect calcium absorption \[[@pone.0235163.ref020]\] and that the suppression of vacuolar H^+^~-~ATPase in bone inhibits bone resorption, thus increasing fracture risk \[[@pone.0235163.ref021], [@pone.0235163.ref022]\]. However, the association between PPI use and decrease in bone density has yet to be property elucidated \[[@pone.0235163.ref023], [@pone.0235163.ref024]\]. There may be other viable mechanisms behind the PPI-induced fracture risk other than impaired bone structure. Despite research findings that PPI use is associated with hyperparathyroidism and hypocalcemia, it is still unclear whether PPI use induces hypocalcemia and secondary hyperparathyroidism or whether gastrointestinal disorders caused by hyperparathyroidism or hypocalcemia increase PPI use \[[@pone.0235163.ref025]\].

BP is a drug used for the treatment of osteoporosis, and it works by increasing bone density by suppressing osteoclasts \[[@pone.0235163.ref026]\]. PPIs are used widely to prevent or treat upper gastrointestinal disorders, one of the major side effects of BP \[[@pone.0235163.ref013]\]. BP adherence has also been reported as an interactive mechanism for increasing the PPI-induced fracture risk in BP users. BP users are likely to sustain gastrointestinal disorders as a side effect of BP, which may result in a low BP adherence and thus decrease the anti-fracture effect of BP \[[@pone.0235163.ref013]\]. However, the study conducted by Lee et al. that demonstrated the interaction between BP and PPIs, no difference in BP adherence was observed in the PPI exposure and non-exposure groups among the BP users \[[@pone.0235163.ref016]\]. Both BP and PPIs suppress osteoclasts, and their interactive mechanism is explained by chronically impaired bone remodeling, which makes bone prone to fracture, while maintaining bone density. The usual dose of PPIs for treating gastrointestinal disorders is known to be too low to reach a blood concentration high enough to affect osteoclasts, which makes it implausible to explain the mechanism with PPIs alone. However, the pharmacological interactions of BP and PPIs administered together at their respective usual clinical doses have yet to be clarified through further research.

Unlike other studies conducted in Korea, this study used data generated after the rapid increase in the use of PPIs, and thus the derived analysis results reflect the characteristics of current PPI users. Another advantage of this study was its observation period of 3 years, which is neither too long to prevent the dilution of the association between PPI use and fracture risk nor too short to observe the effects of long-term PPI use.

This study had some limitations. Given the nature of health insurance claim data, there are no detailed descriptions of the patients' clinical features, so our analysis was based only on the patient information obtained from the disease codes required for insurance claims. Although some clinical parameters, such as BMD, are closely related to the risk of fracture \[[@pone.0235163.ref027]\], the database used in this study could not provide this information and thus did not reflect it. Since osteoporosis, which had a significant effect on fractures in this study, is a disease with few external symptoms, it is likely that a large number of patients without a diagnosis of osteoporosis were included in the study population. In fact, cases included in this study were defined as patients with osteoporotic fractures; however, approximately 34% of these cases had been diagnosed with osteoporosis before the fracture occurred, and 67% were diagnosed with osteoporosis based on active diagnostic tests following the fracture. Thus, we can assume that the control group may have included undiagnosed osteoporosis patients. Since PPI use is known to increase the risk of fractures, the diagnosis of osteoporosis is a factor that may affect PPI prescription. In other words, the prescription of PPIs for the treatment of gastrointestinal diseases may be avoided in patients diagnosed with osteoporosis. Therefore, in this study, the diagnosis of osteoporosis before the event date is considered a factor that may influence the drug selection of patients. We tried to minimize the effects of misclassification related to osteoporosis by using the diagnosis of osteoporosis before the event date as a matching variable.

Although life style variables, such as smoking, alcohol, physical activity, and body weight are important factors affecting BMD \[[@pone.0235163.ref027]\], this study did not use them as covariates. As the lifestyle information presented in [Table 1](#pone.0235163.t001){ref-type="table"} was obtained from the national health examination database, the time of measurement could not be specified, and the "unknown" ratio was more than half. Hence, it seemed inaccurate to include these parameters as covariates. Smoking or obesity are risk factors for fractures as well as gastric ulcers or GERD \[[@pone.0235163.ref028]\]. Smokers and obese people are more likely to use PPI to treat gastrointestinal problems, and the case group might have had a higher proportion of smokers and obese people and PPI users. However, this study performed in the nested cohort included patients with peptic ulcer or GERD. As all subjects had gastrointestinal problems, we minimized the impact of the mechanism described above as a confounding factor in the findings.

Furthermore, we could not account for factors such as the use of calcium supplements due to a lack of available information on dietary supplements or over-the-counter drugs. Moreover, due to the nature of a case-control study, it was impossible to demonstrate a direct causal relationship between PPI use and fracture risk and the underlying mechanisms. In the use of PPIs and BP, the temporal and sequential relationships could not be reflected in the analysis given that there were many limitations in inferring the mechanisms by which their interactions affect fracture incidence. Therefore, care should be taken in interpreting the results of this study.

Nevertheless, this study has some strengths. We considered issues related to time in case-control matching to minimize the time-related bias (time-window bias) that is likely to occur in case-control studies \[[@pone.0235163.ref029]\]. The same event date was assigned to the case and matched controls, and the same observation period of 3 years was applied from the event date for both groups. Thus, this study design eliminated the tendency of over-representation of unexposed cases, which could be caused by differences in the length of observation period between case and control.

In conclusion, the results of this study showed that care should be taken when administering PPIs to elderly women at high risk of fracture, especially in cases of long-term medication use. Particular caution is warranted when prescribing BP for patients who are also using PPIs.

This study analyzed NIHSS data (NHIS-2018-1-391) provided by the Korean National Health Insurance Service (NHIS). The authors declare no potential conflicts of interest with NHIS with respect to the authorship and/or publication of this article.
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors conducted a nested case-control study to reconfirm (i) the association between the proton-pump inhibitors (PPI) usage and fracture risks, and (ii) the interaction between bisphosphonate (BP) and PPI in long-term users. The Korean National Health Insurance Sharing Service database covering the period Jan 2007 to Dec 2017 was used. The study subjects who had sustained at least one osteoporotic fracture, operationally defined as a "diagnosis of osteoporosis prior to or within three months of the fracture diagnosis or osteoporosis with current pathological fracture" were identified as cases. It is not clear how fracture was identified from the database, and whether all or only three specific fractures (i.e. "wrist, spine, femur") were examined in the study. Two controls who had no history of osteoporotic fracture were matched by age, the presence of osteoporosis and the Charlson comorbidity index. The study subjects who had had any fracture within three years prior to the event date (i.e. the fracture date for cases) were excluded from the analyses. The conditional logistic regression analyses, additionally accounting for Charlson index, comorbidities and medications revealed an increased odds of any fracture associated with PPI (aOR: 1.15; 95% CI: 1.11, 1.20). Interestingly, the study also reconfirmed the interaction between BP and PPI in long-term users regardless of the trivial difference (1.15 (95% CI: 1.08, 1.92) in BP users vs. 1.11 (1.03, 1.20) in BP non-users).

The manuscript is overall informative. However, the authors might wish to address the following issues in the subsequent submission.

Major issues:

1\. Study rationale

Several meta-analyses, such as Zhou B et al (cited as reference 18 in the manuscript) or Nassar Y et al (reference 19) have indicated the association between PPI and fracture risk, including hip fracture risk. The long-term PPI therapy and hip fracture risk was also investigated in a large nested case-control study of 13,556 hip fracture cases and 135,386 controls (i.e. Yang X et al, reference 20). Given the current literature, the authors are expected to make their study rationales stronger and much more convincingly. Speculation of how the findings would be used in clinical practice would be also useful to justify the study rationale.

2\. Osteoporosis diagnosis and definition of osteoporotic fracture

It appears that diagnosis of osteoporosis is prerequisite to operationally define an osteoporotic fracture ("An osteoporotic fracture was defined as a diagnosis of osteoporosis prior to or within three months of the fracture (wrist, spine, femur) or osteoporosis with current pathological fracture"). However, approximately 66% of the cases had osteoporosis comorbidity reported (Table 1). Please explain how cases (i.e. the study subjects with an osteoporotic fracture) who did not have osteoporosis diagnosis were selected.

Similarly, the authors also acknowledged "a large number of patients without a diagnosis of osteoporosis were included in the control group". Further clarification would be useful as the controls were matched by osteoporosis diagnosis known as a prerequisite condition for selecting cases.

3\. Fracture types

I believe that the study might have aimed to examine all fracture types, but only three specific fractures ("wrist, spine, femur") were mentioned in the manuscript. Importantly, it is not clear how a fracture was identified (i.e. using ICD 10 codes or self-report) and which fracture types were included.

Please verify how a fracture was identified in this study. If ICD 10 codes were used to capture a fracture, these ICD 10 codes should be provided, at least as an appendix table. If the study indeed examined only three specific fractures, please justify the reasons why these specific fractures were selected, how they were identified, and whether "femur" included hip fracture.

The authors might also wish to discuss how misclassification of osteoporotic fracture, such as a traumatic fracture reported in a patient with osteoporosis diagnosis was possible and how it might affect their findings.

4\. Validation of diagnoses derived from this database

It would be useful if the authors could explain how accurate and reliable the diagnoses derived from reported ICD 10 codes. Are there published efforts to validate these diagnoses? If not, the authors should acknowledge and discuss potential impact of any misclassification on their findings.

5\. Statistical analysis

In addition to the matching design, it is reasonable to make adjustment for several covariates such as Charlson comorbidity index, comorbidities and medication. The adjusted analyses actually attenuated the association between PPI and any fracture risk (from 1.39 (95% CI: 1.35, 1.44) to 1.15 (1.11, 1.20). Please make clear whether these covariates were predefined or data driven.

The authors are expected to justify why the analyses did not account for other known risk factors of fracture (such as smoking, physical activity and importantly, BMI as a proxy of BMD) that might have confounded the association between PPI and fracture risk. The authors might also wish to present the results of analyses accounting for all potential confounding effects, to at least confirm the robustness of the findings, even though such analyses were not predefined.

6\. Possible impact of immortal time bias on the findings

The study also reported an increased fracture risk associated with increased duration of PPI use (Table 2). As the treatment was not randomly allocated, patients with longer duration of PPI would be possibly followed long enough to sustain a fracture, while those with short treatment duration might have died before they had a chance to sustain a fracture (i.e. an immortal time bias). Given its commonness in observational pharmaco-epidemiological studies, please discuss whether and how this immortal bias would impact the findings.

Minor issues:

\- Categorization of duration of PPI was purely data driven. Are other more clinically relevant categorizations available? If so, the authors might wish to consider a sensitivity analysis using more clinically relevant categorisation of PPI duration.

Reviewer \#2: This is a nested case-control epidemiological study of elderly females with a diagnosis of peptic ulcer disease or GERD from a Korean National Health Insurance Sharing Service. The results confirm previous studies and meta-analyses that indicate a significant association between use of proton pump inhibitors and osteoporotic fractures. In addition, a significant interaction was found between PPI and bisphosphonate use and fracture risk. The study is well done with clearly-stated results.

1\. The authors required a diagnosis of osteoporosis prior to or within 3 months of a fracture for the case group. Please specify whether the diagnosis of osteoporosis was made by bone density studies or by a clinical diagnosis.

2\. Many fractures in elderly patients occur in the absence of osteoporosis. Would the results differ if all patients with fragility fractures were included in the case group regardless of whether they had an ICD-10 diagnosis of osteoporosis?

3\. Please indicate how "urban" differs from "metropolitan" in this data base.
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]
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Thanks for two reviewers' kind comments on our paper. We did reflect the matters you pointed out as much as possible. Please find the uploaded file_response to reviewers.

Reviewer \#1:

Major issues:

1\. Study rationale

Several meta-analyses, such as Zhou B et al (cited as reference 18 in the manuscript) or Nassar Y et al (reference 19) have indicated the association between PPI and fracture risk, including hip fracture risk. The long-term PPI therapy and hip fracture risk was also investigated in a large nested case-control study of 13,556 hip fracture cases and 135,386 controls (i.e. Yang X et al, reference 20). Given the current literature, the authors are expected to make their study rationales stronger and much more convincingly. Speculation of how the findings would be used in clinical practice would be also useful to justify the study rationale.

In accordance with the important points you gave, the clinical meaning has been further refined as follows:

It is significant that the association between PPI use and the risk of fracture especially depending on bisphosphonate(BP) exposure in Korean medical environment different from previous studies, was confirmed in a similar pattern. The study results could be used as an evidence for clinicians to make a decision for more effective and safe treatment of gastrointestinal problems in elderly with long-term PPI usage, especially women aged 65 and older at high risk of fracture.

2\. Osteoporosis diagnosis and definition of osteoporotic fracture

It appears that diagnosis of osteoporosis is prerequisite to operationally define an osteoporotic fracture ("An osteoporotic fracture was defined as a diagnosis of osteoporosis prior to or within three months of the fracture (wrist, spine, femur) or osteoporosis with current pathological fracture"). However, approximately 66% of the cases had osteoporosis comorbidity reported (Table 1). Please explain how cases (i.e. the study subjects with an osteoporotic fracture) who did not have osteoporosis diagnosis were selected.

Similarly, the authors also acknowledged "a large number of patients without a diagnosis of osteoporosis were included in the control group". Further clarification would be useful as the controls were matched by osteoporosis diagnosis known as a prerequisite condition for selecting cases.

We applied different time periods for osteoporosis evaluation to select cases and for comorbidity assessment to explain patient characteristics.

In order to select the case, subjects were evaluated for 3 months after the fracture and whole history period before the fracture. Comorbidities described in Table 1 were evaluated for 1 year before the fracture.

We used data about osteoporosis and CCI for 1-year before the fracture as a matching variable because osteoporosis diagnosis probably affect the choice of drug.

These explanation have been added in the Discussion.

3\. Fracture types

I believe that the study might have aimed to examine all fracture types, but only three specific fractures ("wrist, spine, femur") were mentioned in the manuscript. Importantly, it is not clear how a fracture was identified (i.e. using ICD 10 codes or self-report) and which fracture types were included.

Please verify how a fracture was identified in this study. If ICD 10 codes were used to capture a fracture, these ICD 10 codes should be provided, at least as an appendix table. If the study indeed examined only three specific fractures, please justify the reasons why these specific fractures were selected, how they were identified, and whether "femur" included hip fracture.

The authors might also wish to discuss how misclassification of osteoporotic fracture, such as a traumatic fracture reported in a patient with osteoporosis diagnosis was possible and how it might affect their findings.

ICD10 codes for fractures have been inserted in Method.

Chief clinical manifestations of osteoporosis are vertebral and hip fractures, and wrist fracture are obviously affected by osteoporosis. Therefore, only three major fractures due to osteoporosis (spine wrist and hip), were defined as events interested in this study.

As you pointed out, it is possible that some trauma fractures are included, but osteoporotic bone is more likely to fracture than is normal bone at any level of trauma. So a fracture with osteoporosis diagnosis defined as an osteoporotic fracture regardless of trauma.

(ref. Robert Lindsay and Felicia Cosman. Chapter 404: osteoporosis. McGraw-Hill Education. Harrison's principle of internal medicine. 20th ed.)

4\. Validation of diagnoses derived from this database

It would be useful if the authors could explain how accurate and reliable the diagnoses derived from reported ICD 10 codes. Are there published efforts to validate these diagnoses? If not, the authors should acknowledge and discuss potential impact of any misclassification on their findings.

The database used in this study covers the entire population with a single National Health Insurance in Korea, and it has the advantage of minimizing recall bias that is common in case-control studies. But it has not been validated for the accuracy and reliability of the diagnoses from the database, since it build up for insurance claims.

In particular, in the case of osteoporosis, the diagnosis is often missed when there are no special events or symptoms, and as noted above, it is difficult to distinguish traumatic fractures. Please kindly refer to the above mentioned explanation and revised Discussion.

5\. Statistical analysis

In addition to the matching design, it is reasonable to make adjustment for several covariates such as Charlson comorbidity index, comorbidities and medication. The adjusted analyses actually attenuated the association between PPI and any fracture risk (from 1.39 (95% CI: 1.35, 1.44) to 1.15 (1.11, 1.20). Please make clear whether these covariates were predefined or data driven.

The authors are expected to justify why the analyses did not account for other known risk factors of fracture (such as smoking, physical activity and importantly, BMI as a proxy of BMD) that might have confounded the association between PPI and fracture risk. The authors might also wish to present the results of analyses accounting for all potential confounding effects, to at least confirm the robustness of the findings, even though such analyses were not predefined.

All covariates are predefined as factors known to be fracture risk or preventive factors, based on previous research or literature.

Variables related with lifestyle were not included as covariates in the analysis. Since the data originated from national health examination, the time of measurement could not be specified and the "unknown" ratio was more than half. So it seemed inaccurate to use as covariates. Smoking or obesity are risk factors for fractures, gastric ulcers or GERD. Smokers and obese people are more likely to use PPI to treat gastrointestinal problems, and the case group may have higher proportion of them and PPI users. However, this study performed in the nested cohort with patients with peptic ulcer or GERD. Since all subjects have gastrointestinal problems, the mechanism described above is unlikely to be a confounding factor in the findings.

We agree that BMD value is very important variable for fracture, but unfortunately the Korean National Health Insurance Sharing Service (NIHSS) database we used in this study does not include BMD value of the patients.

6\. Possible impact of immortal time bias on the findings

The study also reported an increased fracture risk associated with increased duration of PPI use (Table 2). As the treatment was not randomly allocated, patients with longer duration of PPI would be possibly followed long enough to sustain a fracture, while those with short treatment duration might have died before they had a chance to sustain a fracture (i.e. an immortal time bias). Given its commonness in observational pharmaco-epidemiological studies, please discuss whether and how this immortal bias would impact the findings.

In the cohort study design, the immortal time bias may be an important consideration, but in this case-control study where we select a subject who has developed a disease and then assess his/her past history, the subject who died or censored follow up is not included in the observation. We think that there might be a little impact of the immortal time bias in this study.

Minor issues:

\- Categorization of duration of PPI was purely data driven. Are other more clinically relevant categorizations available? If so, the authors might wish to consider a sensitivity analysis using more clinically relevant categorisation of PPI duration.

The classification of duration of PPI use was simply predefined with a reference to previous studies. We agreed to your suggestion for more clinically relevant categorization of PPI exposure duration.

But, the database we used in this study was allowed to access remotely for a limited time we proposed.

Now the database had been closed, so an additional analysis to apply the new classification requires a lot of time and new process to acquire the data. We would like to consider what you have pointed out in the further study.

Reviewer \#2:

1\. The authors required a diagnosis of osteoporosis prior to or within 3 months of a fracture for the case group. Please specify whether the diagnosis of osteoporosis was made by bone density studies or by a clinical diagnosis.

As per your comment, ICD 10 codes for fractures have been inserted.

2\. Many fractures in elderly patients occur in the absence of osteoporosis. Would the results differ if all patients with fragility fractures were included in the case group regardless of whether they had an ICD-10 diagnosis of osteoporosis?

Last year, we had conducted a similar study for the case group regardless of whether they had an ICD-10 diagnosis of osteoporosis in adults aged 50 and more, and results were similar with this study. As we establish a hypothesis that PPI increases the fracture risk via osteoporosis, we limit the association between PPI and osteoporotic fracture among the population with high risk of osteoporosis in this study.

3\. Please indicate how "urban" differs from "metropolitan" in this data base.

Residential areas were classified according to the definition below and the definition has been added in the Table 1.

� Metropolitan: A local government with boroughs

� Cities: A local government with a population of 50,000 or more without a borough

� Rural area: A local government with a population less than 50,000

10.1371/journal.pone.0235163.r003
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Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I would like to thank the authors for their time and efforts to address my concerns. There are however several minor issues they might wish to address more convincingly.

1\. Study rationale

The authors provided speculations on how the findings would be useful. However, I found "the studies lack information on long-term users. Therefore, we need to reconfirm the influence of the interaction between BP and PPIs on fracture risk in long-term PPI users" not convincing enough.

I understand that the authors aimed to "reconfirm" the previous findings. However, they are expected to make the novelties and rationales far clearer and more convincing. More specifically, please clarify how the current findings could contribute to the current science knowledge on top of the previous findings from several meta-analyses (references 18, 19) and a very large nested case-control study (reference 20).

2\. I agree with what the authors explained about covariates in the analyses. However, I'd like to suggest them to add the explanation they made for weight and BMD into the manuscript, which would make their analyses more convincing.

3\. Possible time-related biases

I am sorry that my concerns about time-related biases (which was wrongly written as an immortal bias) might have caused a misunderstanding. While I agree with the authors that an immortal bias might not be problematic in their case-control study, I think it is worth discussing further the potential contribution, if any of time-related biases, especially the time-window bias. It is important as the cases and controls were matched by age, osteoporosis diagnosis and Charlson index. It would be an important strength if the time-related biases were already accounted for.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Thach Tran

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

21 May 2020

Thanks for reviewer\#1\'s kind comments on our paper. We did reflect the matters you pointed out as much as possible.

1\. Study rationale : The authors provided speculations on how the findings would be useful. However, I found "the studies lack information on long-term users. Therefore, we need to reconfirm the influence of the interaction between BP and PPIs on fracture risk in long-term PPI users" not convincing enough. I understand that the authors aimed to "reconfirm" the previous findings. However, they are expected to make the novelties and rationales far clearer and more convincing. More specifically, please clarify how the current findings could contribute to the current science knowledge on top of the previous findings from several meta-analyses (references 18, 19) and a very large nested case-control study (reference 20).

Author's reply: Thank you for your comments regarding the study novelties. Basically we agreed with you because a novelty is important in academic researches. As we thought our study had the following strengths comparing to previous studies on the same topic. We have added three points separately in the Discussion.

� There were discrepancies in the relationship between the duration of PPI use and fracture risk in the previous meta-analyses, due to applying different definitions of the PPI exposure duration in those studies. Considering the mechanism by which PPI use increases the risk of fracture, our study defined the PPI exposure duration as the cumulative prescription days for 3 years for each subject. With the strength of such research design, we could identify more robust association between PPI use and fracture risk. \[Revised manuscript page 12, line 240\~247\]

� Considering that PPI is the major drug indicated for GERD which affect fractures, this study was conducted only for patients with GERD or gastric ulcer. We enrolled patients with diagnosis of GERD or gastric ulcer, and the association of PPI use and fracture risk was analyzed for the cohort. This approach probably minimized confounding effect related with both gastric problems and fractures \[Revised manuscript page 15, line 314\~323\]

� We applied the same 3-year observation period on PPI exposure before index date (or same date in matching control) to both cases and controls. 3-years is a comparatively long-term observation than the previous studies, and the same length of the observation period could make time-window bias minimize. \[Revised manuscript page 15, line 332\~337\]

2\. I agree with what the authors explained about covariates in the analyses. However, I'd like to suggest them to add the explanation they made for weight and BMD into the manuscript, which would make their analyses more convincing.

Author's reply: Thank you. As per your suggestion, we have added the explanation in the Discussion. \[Revised manuscript page 15, line 314\~313\]

3\. Possible time-related biases : I am sorry that my concerns about time-related biases (which was wrongly written as an immortal bias) might have caused a misunderstanding. While I agree with the authors that an immortal bias might not be problematic in their case-control study, I think it is worth discussing further the potential contribution, if any of time-related biases, especially the time-window bias. It is important as the cases and controls were matched by age, osteoporosis diagnosis and Charlson index. It would be an important strength if the time-related biases were already accounted for.

Author's reply: Thank you for pointing out what we missed. You are right. The same event date and the same observation period were assigned to both cases and controls in our study, which make the possibility of time-window bias minimize. Accordingly, we added this sentences in the Discussion, as the above mentioned in the Answer \#1. \[Revised manuscript page 15, line 332\~337\]
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Association between proton pump inhibitor use and risk of fracture: a population-based case-control study.

PONE-D-19-30609R2

Dear Dr. Sohn,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Robert Daniel Blank, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I'd like to thank the authors for their efforts to address my concerns. There are two minor issues the authors might wish to address to make the manuscript more convincing.

1\. The authors has indicated the novel definition of PPI exposure "as the cumulative prescription days for 3 years for each subject". The authors might wish to add a couple of sentences to clarify how this novel operational definition is better than the previous ones, making the statement "to identify more robust association between PPI use and fracture risk" justified.

The authors might wish to use the evidence related to biological mechanism (i.e. how the novel definition is more biologically rationale) or research methodology (i.e. how it is methodologically less biased), rather than an overall, somewhat vague statement.

2\. Similarly, please give an example of a confounding effect that the study was successfully able to account for. Such an example would be also useful to make the statement "This approach probably minimized confounding effect related with both gastric problems and fractures" clearer and more convincing.

Looking forward to receiving your response soon.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Thach Tran

Reviewer \#2: No
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Association between proton pump inhibitor use and risk of fracture: a population-based case-control study.

Dear Dr. Sohn:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Robert Daniel Blank

Academic Editor
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